HC Wainwright Issues Pessimistic Outlook for BDTX Earnings

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) – Research analysts at HC Wainwright reduced their Q1 2025 EPS estimates for shares of Black Diamond Therapeutics in a report issued on Tuesday, March 18th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($0.32) per share for the quarter, down from their prior estimate of ($0.31). HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Black Diamond Therapeutics’ current full-year earnings is ($1.30) per share. HC Wainwright also issued estimates for Black Diamond Therapeutics’ Q2 2025 earnings at ($0.33) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.34) EPS and FY2025 earnings at ($1.32) EPS.

Several other analysts also recently issued reports on BDTX. Stifel Nicolaus lowered their price objective on shares of Black Diamond Therapeutics from $16.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, March 7th. Wedbush reiterated an “outperform” rating and set a $11.00 target price on shares of Black Diamond Therapeutics in a research note on Wednesday. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $14.60.

Black Diamond Therapeutics Stock Down 5.3 %

Shares of NASDAQ:BDTX opened at $1.78 on Thursday. Black Diamond Therapeutics has a 52-week low of $1.59 and a 52-week high of $7.66. The company has a 50 day moving average of $2.16 and a two-hundred day moving average of $2.89. The company has a market capitalization of $100.86 million, a price-to-earnings ratio of -1.34 and a beta of 2.52.

Black Diamond Therapeutics (NASDAQ:BDTX) last issued its quarterly earnings data on Thursday, March 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.03.

Hedge Funds Weigh In On Black Diamond Therapeutics

Large investors have recently added to or reduced their stakes in the company. D. E. Shaw & Co. Inc. bought a new position in Black Diamond Therapeutics during the fourth quarter worth $37,000. Intech Investment Management LLC lifted its stake in Black Diamond Therapeutics by 49.1% during the fourth quarter. Intech Investment Management LLC now owns 19,247 shares of the company’s stock worth $41,000 after purchasing an additional 6,340 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Black Diamond Therapeutics by 429.6% during the fourth quarter. JPMorgan Chase & Co. now owns 18,929 shares of the company’s stock worth $41,000 after purchasing an additional 15,355 shares during the last quarter. SG Americas Securities LLC bought a new position in Black Diamond Therapeutics during the fourth quarter worth $42,000. Finally, Wells Fargo & Company MN lifted its stake in Black Diamond Therapeutics by 41.8% during the fourth quarter. Wells Fargo & Company MN now owns 20,119 shares of the company’s stock worth $43,000 after purchasing an additional 5,932 shares during the last quarter. 95.47% of the stock is currently owned by institutional investors.

Insider Activity

In related news, major shareholder Growth N. V. Biotech sold 5,784,292 shares of the firm’s stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $2.07, for a total transaction of $11,973,484.44. Following the transaction, the insider now directly owns 2,733,547 shares in the company, valued at $5,658,442.29. This trade represents a 67.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 8.87% of the company’s stock.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.